CLINICAL_TRIALS
trial_result
· 2023-05-06
Clinical Trial Update: RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE [Phase 2]
Summary
Phase 2 trial of RTA 408 Lotion in breast cancer patients at risk for radiation dermatitis has completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biogen | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-05-06